Immunosuppressive Effect of Compound K on Islet Transplantation in an STZ-Induced Diabetic Mouse Model
Authors:
Open Access
- 15 September 2014
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 63 (10) , 3458-3469
Abstract
Islet transplantation is a therapeutic option for type 1 diabetes, but its long-term success is limited by islet allograft survival. Many factors imperil islet survival, especially the adverse effects and toxicity due to clinical immunosuppressants. Compound (Cpd) K is a synthesized analog of highly unsaturated fatty acids from Isatis tinctoria L.(Cruciferae). Here we investigated the therapeutic effect of Cpd K in diabetic mice and found that it significantly prolonged islet allograft survival with minimal adverse effects after 10 days. Furthermore, it reduced the proportion of CD4+ and CD8+ T cells in spleen and lymph nodes, inhibited inflammatory cell infiltration in allografts, suppressed serum interleukin-2 and interferon-γ secretion, and increased transforming growth factor-β and Foxp3 mRNA expression. Surprisingly, Cpd K and rapamycin had a synergistic effect. Cpd K suppressed proliferation of naïve T cells by inducing T-cell anergy and promoting the generation of regulatory T cells. In addition, nuclear factor-κB signaling was also blocked. Taken together, these findings indicate that Cpd K may have a potential immunosuppressant effect on islet transplantation.Keywords
This publication has 47 references indexed in Scilit:
- Transplant Tolerance to Pancreatic Islets Is Initiated in the Graft and Sustained in the SpleenAmerican Journal of Transplantation, 2013
- A Novel Role of Dma1 in Regulating Forespore Membrane Assembly and Sporulation in Fission YeastMolecular Biology of the Cell, 2010
- The impact of natural products upon modern drug discoveryCurrent Opinion in Chemical Biology, 2008
- A critical function for TGF-β signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cellsNature Immunology, 2008
- Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytesNature Medicine, 2007
- Recovery from diabetes in mice by β cell regenerationJournal of Clinical Investigation, 2007
- The evolving role of natural products in drug discoveryNature Reviews Drug Discovery, 2005
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- Type I Diabetes MellitusNew England Journal of Medicine, 1986
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975